309 related articles for article (PubMed ID: 31960363)
21. A potential prognostic long non-coding RNA signature to predict metastasis-free survival of breast cancer patients.
Sun J; Chen X; Wang Z; Guo M; Shi H; Wang X; Cheng L; Zhou M
Sci Rep; 2015 Nov; 5():16553. PubMed ID: 26549855
[TBL] [Abstract][Full Text] [Related]
22. Decreased TCL6 expression is associated with poor prognosis in patients with clear cell renal cell carcinoma.
Su H; Sun T; Wang H; Shi G; Zhang H; Sun F; Ye D
Oncotarget; 2017 Jan; 8(4):5789-5799. PubMed ID: 27494890
[TBL] [Abstract][Full Text] [Related]
23. PD-L1 expression and tumor infiltrating PD-1+ lymphocytes associated with outcome in HER2+ breast cancer patients.
Tsang JY; Au WL; Lo KY; Ni YB; Hlaing T; Hu J; Chan SK; Chan KF; Cheung SY; Tse GM
Breast Cancer Res Treat; 2017 Feb; 162(1):19-30. PubMed ID: 28058578
[TBL] [Abstract][Full Text] [Related]
24. Colorectal Cancer-Associated Immune Exhaustion Involves T and B Lymphocytes and Conventional NK Cells and Correlates With a Shorter Overall Survival.
Sorrentino C; D'Antonio L; Fieni C; Ciummo SL; Di Carlo E
Front Immunol; 2021; 12():778329. PubMed ID: 34975867
[TBL] [Abstract][Full Text] [Related]
25. LAYN Is a Prognostic Biomarker and Correlated With Immune Infiltrates in Gastric and Colon Cancers.
Pan JH; Zhou H; Cooper L; Huang JL; Zhu SB; Zhao XX; Ding H; Pan YL; Rong L
Front Immunol; 2019; 10():6. PubMed ID: 30761122
[No Abstract] [Full Text] [Related]
26. A novel immune-related prognostic index for predicting breast cancer overall survival.
Yu X; Guo J; Zhou Q; Huang W; Xu C; Long X
Breast Cancer; 2021 Mar; 28(2):434-447. PubMed ID: 33146847
[TBL] [Abstract][Full Text] [Related]
27.
Chen B; Lai J; Dai D; Chen R; Li X; Liao N
Aging (Albany NY); 2019 Dec; 11(23):11124-11135. PubMed ID: 31790361
[TBL] [Abstract][Full Text] [Related]
28. PD-L1 correlated gene expression profiles and tumor infiltrating lymphocytes in pancreatic cancer.
Li J; Yin L; Chen Y; An S; Xiong Y; Huang G; Liu J
Int J Med Sci; 2021; 18(14):3150-3157. PubMed ID: 34400885
[No Abstract] [Full Text] [Related]
29. Up-regulated lncRNA AFAP1-AS1 indicates a poor prognosis and promotes carcinogenesis of breast cancer.
Ma D; Chen C; Wu J; Wang H; Wu D
Breast Cancer; 2019 Jan; 26(1):74-83. PubMed ID: 29974352
[TBL] [Abstract][Full Text] [Related]
30. A Novel Prognostic Signature of mRNA-lncRNA in Breast Cancer.
Liu Q; Wang Z; Kong X; Wang X; Qi Y; Gao R; Fang Y; Wang J
DNA Cell Biol; 2020 Apr; 39(4):671-682. PubMed ID: 32040341
[TBL] [Abstract][Full Text] [Related]
31. An immune cell infiltration-based immune score model predicts prognosis and chemotherapy effects in breast cancer.
Sui S; An X; Xu C; Li Z; Hua Y; Huang G; Sui S; Long Q; Sui Y; Xiong Y; Ntim M; Guo W; Chen M; Deng W; Xiao X; Li M
Theranostics; 2020; 10(26):11938-11949. PubMed ID: 33204321
[No Abstract] [Full Text] [Related]
32. Prognostic value of tumor infiltrating lymphocyte subsets in breast cancer depends on hormone receptor status.
Chung YR; Kim HJ; Jang MH; Park SY
Breast Cancer Res Treat; 2017 Feb; 161(3):409-420. PubMed ID: 27913931
[TBL] [Abstract][Full Text] [Related]
33. The potential role of abnormal angiotensin-converting enzyme 2 expression correlated with immune infiltration after SARS-CoV-2 infection in the prognosis of breast cancer.
Jiang Y; Chen L; Shen J; Mei X; Yao J; Chen T; Zhou Y
Aging (Albany NY); 2021 Aug; 13(17):20886-20895. PubMed ID: 34413267
[TBL] [Abstract][Full Text] [Related]
34. The prognostic value of long noncoding RNA HOTTIP on clinical outcomes in breast cancer.
Yang Y; Qian J; Xiang Y; Chen Y; Qu J
Oncotarget; 2017 Jan; 8(4):6833-6844. PubMed ID: 28036281
[TBL] [Abstract][Full Text] [Related]
35. Immunophenotype-associated gene signature in ductal breast tumors varies by receptor subtype, but the expression of individual signature genes remains consistent.
Behring M; Ye Y; Elkholy A; Bajpai P; Agarwal S; Kim HG; Ojesina AI; Wiener HW; Manne U; Shrestha S; Vazquez AI
Cancer Med; 2021 Aug; 10(16):5712-5720. PubMed ID: 34189853
[TBL] [Abstract][Full Text] [Related]
36. Regulation and characterization of tumor-infiltrating immune cells in breast cancer.
Dai Q; Wu W; Amei A; Yan X; Lu L; Wang Z
Int Immunopharmacol; 2021 Jan; 90():107167. PubMed ID: 33223469
[TBL] [Abstract][Full Text] [Related]
37. Effect of neoadjuvant chemotherapy on tumor-infiltrating lymphocytes and PD-L1 expression in breast cancer and its clinical significance.
Pelekanou V; Carvajal-Hausdorf DE; Altan M; Wasserman B; Carvajal-Hausdorf C; Wimberly H; Brown J; Lannin D; Pusztai L; Rimm DL
Breast Cancer Res; 2017 Aug; 19(1):91. PubMed ID: 28784153
[TBL] [Abstract][Full Text] [Related]
38. High expression of long non-coding RNA MALAT1 in breast cancer is associated with poor relapse-free survival.
Wang Z; Katsaros D; Biglia N; Shen Y; Fu Y; Loo LWM; Jia W; Obata Y; Yu H
Breast Cancer Res Treat; 2018 Sep; 171(2):261-271. PubMed ID: 29845475
[TBL] [Abstract][Full Text] [Related]
39. A novel long non-coding RNA FGF14-AS2 is correlated with progression and prognosis in breast cancer.
Yang F; Liu YH; Dong SY; Ma RM; Bhandari A; Zhang XH; Wang OC
Biochem Biophys Res Commun; 2016 Feb; 470(3):479-483. PubMed ID: 26820525
[TBL] [Abstract][Full Text] [Related]
40. Prognostic significance of interferon regulating factor 4 (IRF4) in node-negative breast cancer.
Heimes AS; Madjar K; Edlund K; Battista MJ; Almstedt K; Gebhard S; Foersch S; Rahnenführer J; Brenner W; Hasenburg A; Hengstler JG; Schmidt M
J Cancer Res Clin Oncol; 2017 Jul; 143(7):1123-1131. PubMed ID: 28251349
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
